17-Oct-2019

Abalos Therapeutics announced a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells generating ...

more

Vacis raises capital from Brightlands Venture Partners, HTGF, LIOF and RVO

14-Oct-2019

Every year, an estimated 300.000 hemodialysis patients worldwide die as they run out of medical alternatives. One of the main reasons for these deaths is failure of the vascular access site, the blood vessel where blood is removed, filtered and returned to the body during dialysis. To solve this ...

more

26-Sep-2019

Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life science and ...

more

18-Sep-2019

Belyntic, a Berlin-based chemistry-for-healthcare startup and developer of the Peptide Easy Clean (PEC) purification technology, has completed its seed financing round amounting to €1.3 million. The funding is led by the Investitionsbank Berlin (IBB), with the High-Tech Gründerfonds (HTGF) also ...

more

17-Jul-2019

Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently ...

more

“First-in-Class“ mRNA-therapeutics for vascular diseases:

04-Jul-2019

Pantherna Therapeutics secures €3.5 million in a successful seed-financing round.The funds will be used to advance R&D activities and hire additional scientific staff. The Investors are the High-Tech Gründerfonds (HTGF), European Business Angel Prof. Detlev Riesner as well as the European ...

more

Investors include Amgen Ventures, HTGF and Hemi Ventures

17-May-2019

NAVAN Technologies, Inc., a privately-held biotechnology company enabling the development of next generation cell and gene therapies through its novel, non-viral NanoStraw platform, announced it had closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi ...

more

08-May-2019

DyNAbind’s Dynamic DNA-Encoded Library technology platform allows hundreds of millions of chemical structures to be simultaneously screened and optimized against a potential drug target protein. This innovation continues to be driven forward with investment from the High-Tech Gründerfonds (HTGF), ...

more

Consortium invests seven-digit amount in serum marker for testicular cancer detection

03-May-2019

Together with BBM and a private investor, High-Tech Gründerfonds (HTGF) is investing a seven-figure sum in the start-up company miRdetect located in Bremen, and founded in 2016. The company founders Meike Spiekermann and Dr. Nina Winter were able to convince the investors with their novel and ...

more

ALENTIS Therapeutics raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer

02-May-2019

ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the ...

more